Using midazolam as a proposed enzyme probe does not demonstrate that bypass or ECMO changed its clearance.
The pilot protocol planned serial assessment of several CYP pathways using a probe cocktail before and after cardiac procedures or during ECMO. Midazolam and its pathway-specific metabolite were included as measures related to CYP3A activity. A laparoscopic-surgery group was proposed for comparison.
The publication contains planned sampling and comparisons rather than observed interaction magnitudes. Extracorporeal support can change distribution, binding, circuit handling and physiology as well as metabolism; a proposed enzyme assay cannot settle those mechanisms by itself.
For an extracorporeal-support opinion, identify which observations are available in the actual record and which remain research hypotheses. Preserve circuit changes, infusion history and specimen times. This protocol supplies a methodological framework, not a measured correction for midazolam concentrations or a demonstrated explanation for delayed awakening.
Source reviewed: Study Protocol for a Pilot Open Label Prospective and Observational Study to Evaluate the Pharmacoki (PMC6632166). Forensic applications above are interpretive analysis of the supplied publication.
Related reading: Dental Oxygen-Support Publication Was a Trial Protocol.